Qlife Holding AB Cash Flow Conversion Efficiency
Qlife Holding AB cash flow conversion efficiency. Based on the latest financial reports, Qlife Holding AB (QLIFE) has a cash flow conversion efficiency ratio of -2.207x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.20 Million ≈ $-452.42K USD) by net assets (Skr1.91 Million ≈ $205.01K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Qlife Holding AB (2019–2025)
Cash flow conversion efficiency of Qlife Holding AB from 2019 to 2025. This chart illustrates how Qlife Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Qlife Holding AB for real-time trading data and today's change.
Qlife Holding AB Cash Flow Conversion Ratio Explained
Qlife Holding AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Qlife Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qlife Holding AB ranked by their cash flow conversion efficiency. Also see Qlife Holding AB market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
0.148x |
|
Opawica Explorations Inc
V:OPW
|
-0.022x |
|
ScandiDos AB
ST:SDOS
|
-0.020x |
|
InZinc Mining Ltd
V:IZN
|
-0.443x |
|
Caledonia Mining Corporation Plc
LSE:CMCL
|
0.050x |
|
Boule Diagnostics AB
ST:BOUL
|
-0.017x |
|
XORTX Therapeutics Inc
V:XRTX
|
-0.319x |
|
BELLUSCURA PLC LS -01
F:9VQ
|
N/A |
Annual Cash Flow Conversion Efficiency for Qlife Holding AB (2019–2025)
The table below shows the annual cash flow conversion efficiency of Qlife Holding AB from 2019 to 2025. Review Qlife Holding AB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-7.51 Million ≈ $-807.98K |
Skr-21.49 Million ≈ $-2.31 Million |
2.862x | -89.06% |
| 2024-12-31 | Skr-1.43 Million ≈ $-153.78K |
Skr-37.37 Million ≈ $-4.02 Million |
26.151x | +1346.70% |
| 2023-12-31 | Skr-23.12 Million ≈ $-2.49 Million |
Skr-41.80 Million ≈ $-4.50 Million |
1.808x | +445.18% |
| 2022-12-31 | Skr91.15 Million ≈ $9.81 Million |
Skr-47.73 Million ≈ $-5.14 Million |
-0.524x | -228.02% |
| 2021-12-31 | Skr163.18 Million ≈ $17.56 Million |
Skr-26.05 Million ≈ $-2.80 Million |
-0.160x | +15.05% |
| 2020-12-31 | Skr89.55 Million ≈ $9.64 Million |
Skr-16.83 Million ≈ $-1.81 Million |
-0.188x | -202.62% |
| 2019-12-31 | Skr62.48 Million ≈ $6.72 Million |
Skr-3.88 Million ≈ $-417.54K |
-0.062x | -- |
About Qlife Holding AB
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Qlife Holding AB (publ) was incorporated in 2019 and is based in Gothenburg, Sweden.